Consequently, a phase 1/2 clinical trial assessed the administration of nelipepimut-S and GM-CSF in high risk BC patients in the adjuvant setting, with booster inoculations every 6 months until trial completion at 5 years. This evidence concerns the gene CSF2 and breast cancer.